4,4-Difluoropiperidine → 4-{1-(2-fluorophenyl)-4-[3-(4-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}phenyl)-1,2,4-oxadiazol-5-yl]-1H-1,2,3-triazol-5-yl}pyridine

Participants

Reaction Steps

The title compound was prepared following the procedure described for Example 94, but starting from 4-(5-(1-(2-fluorophenyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazol-3-yl)benzaldehyde, obtained as described in Example 113, Step 1, (200 mg; 0.48 mmol) and 4,4-difluoropiperidine (168 mg; 0.97 mmol) to give Example 161 as a white solid. 1H NMR: (CDCl3, 400 MHz) δ 8.72 (2H, dd, J=4.5, 1.7 Hz), 8.05 (2H, d, J=8.1 Hz), 7.63-7.52 (2H, m), 7.45 (2H, d, J=8.0 Hz), 7.40-7.34 (3H, m), 7.22-7.15 (1H, m), 3.61 (2H, s), 2.57 (4H, t, J=5.4 Hz), 2.07-1.94 (4H, m). LC/MS (Method C): 518 (M+H)+. HPLC (Method I) Rt 15.55 min (Purity: 97.6%).

Provenance & Evidence